FDA Approves Necitumumab for Metastatic Squamous NSCLC

Share this content:
The FDA has approved necitumumab (Portrazza) for treatment of metastatic squamous non-small cell lung cancer.
The FDA has approved necitumumab (Portrazza) for treatment of metastatic squamous non-small cell lung cancer.

The U.S. Food and Drug Administration (FDA) has approved necitumumab (Portrazza) in combination with gemcitabine and cisplatin for the treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC) who have not received prior therapy for advanced disease.1

“Lung cancer tumors can be varied, so treatment options need to be tailored to the specific type of lung cancer in the patient,” said Richard Pazdur, MD, director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research. “Today's approval provides certain patients with squamous cell lung cancer a new option that may extend survival.”

Necitumumab is a monoclonal antibody that inhibits epithelial growth factor receptor (EGFR) activity.

Approval was based on an open-label clinical trial that evaluated the safety and efficacy of necitumumab in combination with gemcitabine and cisplatin compared with gemcitabine plus cisplatin alone in 1093 patients with advanced squamous NSCLC. Results showed that median overall survival was 11.5 months with necitumumab vs 9.9 months without it.

The most common adverse events of necitumumab were rash and hypomagnesemia. Healthcare providers should also be aware that necitumumab carries a boxed warning alerting them of serious risks of cardiac arrest and sudden death, and hypomagnesemia in patients taking necitumumab.

RELATED: Alectinib Highly Active, Safe in Advanced Crizotinib-refractory ALK+ NSCLC

Necitumumab was not found to be effective for the treatment of patients with non-squamous NSCLC in a trial that evaluated necitumumab in combination with cisplatin and pemetrexed.

Reference

  1. FDA approves Portrazza to treat advanced squamous non-small cell lung cancer [news release]. Silver Spring, MD: U.S. Food and Drug Administration; November 24, 2015. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncPressA/ucm474131.htm. Accessed November 24, 2015.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters